Data Provided by Refinitiv. Minimum 15 minutes delayed.

MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)


WESTLAKE VILLAGE, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019).

“These data demonstrate that Afrezza’s ultra-rapid onset uniquely affects early post-prandial glucose levels and other measures of mealtime glycemic control,” stated Dr. David Kendall, Chief Medical Officer of MannKind.   

Poster Presentation Highlights

Title: Ultra-rapid Profile of Technosphere® Insulin Inhalation Powder Mimics Time-Action Profile of Physiologic Absorption of Glucose From Mixed-Meal Tolerance Tests in Type 2 Diabetes AACE 2019 Thursday, April 25th (1:30-2:00pm Poster Presentation Area, Monitor 14)

Presenter: David Kendall, MD, Chief Medical Officer, MannKind Corporation


  • Compared to insulin lispro, the ultra-rapid absorption of Afrezza provides significantly better control of early post-prandial glucose levels due to an earlier increase in glucose disposal and a faster suppression of endogenous glucose production.  The duration of this effect is dose dependent.
  • Compared to insulin lispro, Afrezza was associated with lower postprandial glucagon and C-peptide levels and produced a faster decrease in free fatty acid levels.
  • The ultra-rapid profile of Afrezza closely approximates the time-action profile of physiologic insulin needs after a meal in patients with Type 2 Diabetes.

About AACE Annual Meeting

The AACE 2019 conference is an opportunity for healthcare professionals specializing in endocrinology, diabetes, and metabolism to gather to discuss the latest scientific advancements and best practices for enhancing patient care, and enjoy educational sessions led by the world's most respected endocrine clinicians.

About Afrezza®

Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.  Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration.  Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels.  For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit

About MannKind

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit

MannKind Contact:
Rose Alinaya
SVP, Investor Relations


Source: MannKind

Data Provided by Refinitiv. Minimum 15 minutes delayed.